Category: Other Treatments

“The customer is always right” is sometimes wrong, as many companies have learned when disgruntled customers use this slogan as an excuse to speak abusively to employees. As consumers of medical care, prostatectomy patients are also customers, but they often avoid expressing complaints to their surgeon about urinary or sexual side effects of treatment... keep reading

Reviews and ratings are very important in today’s world. Look at the internet. Whether it’s Yelp, Amazon, Ebay, Angie’s List or hundreds more, the number of stars or thumbs up are not as influential as the qualitative comments left by consumers. In similar fashion, radical prostatectomy is... keep reading

It is always thrilling when a treatment is working so well in a clinical trial that the study ends early and the FDA moves rapidly with approval. This was the case with a clinical study called ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer Patients). keep reading

As a treatment for prostate cancer, prostatectomy (surgical gland removal) continues to be dogged by positive surgical margins. Patients who have PSMs are at higher risk for recurrence. The issue is not the surgical approach... keep reading

Thanks to PSA screening and early detection, most prostate cancer is diagnosed while it is still contained in the prostate gland. This implies favorable odds that any whole-gland treatment is potentially curative... keep reading

I have written several blogs on external beam radiation for prostate cancer along with its side effects. Radiation is a good choice for the right patient. As with all prostate cancer treatments, it is essential to match a treatment with an individual’s cancer because many factors go into the choice... keep reading

A PSMA PET/CT scan (or simply PSMA PET) like the one described below that incorporates the radioisotope Gallium-68, is the most sensitive method to detect metastatic prostate cancer (mPCa). PSMA PET has thus quickly gained wide use, including evaluating how well a patient’s mPCa is responding to therapy... keep reading

Urologist Bert Vorstman MD continues to be “a keen observer of the state of prostate cancer.” 1 During an interview for the American Society of Clinical Oncology (ASCO), he made some observations in which he did not mince words... keep reading

The tug-of-war continues between prostate cancer patients who want to be treated with proton beam therapy (PBT) vs. their insurance companies. As you can read from the blog below, payers are denying PCa coverage due to the high cost of the treatment coupled with lack of evidence showing superiority over conventional radiation therapies... keep reading

“Lutetium-177 (¹⁷⁷Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.” Since we posted the 2017 blog below, research into Lutetium-177 has been ongoing. The opening quote for this update comes from a September, 2021 published clinical study by Sartor et al... keep reading